13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MK3475-672

    Acronym: 

    MK3475-672

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Bladder
    Trial Type Treatment
    Phase Phase III Tumour Stream Bladder
    Age Range 18 years and older Cancer Stage All stages
    Sex Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Bladder
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex
    Molecular Target
    Tumour Stream Bladder
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase III randomized, double-blind trial of pembrolizumab in combination with epacadostat or placebo in participants with cisplatin ineligible urothelial carcinoma.

    Lay Summary

    Sponsor / Cooperative group

    Merck

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Not Yet Recruiting